GILD 2Q18 results—total HCV sales $1.0B—(-5% QoQ): http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=2359992 Full-year 2018 guidance tweaked upward due to tax rate.